Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Live Now : Nifty Banker 3.0 | India's First Retail Index Traders Online Conference.
Budget 2023
Budget 2023
you are here: HomeNewsTrendsHealth

NTAGI's COVID working group to review SII's Covovax data for use in 12 year olds and above

India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.

March 30, 2022 / 03:55 PM IST
Representative Image (AFP)

Representative Image (AFP)

A COVID working group of NTAGI will review this week data of Serum Institute of India’s (SII) anti-coronavirus jab Covovax to decide whether it can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above, official sources said on Wednesday.

India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.

Director (Government and Regulatory Affairs) at SII Prakash Kumar Singh recently had written to the health ministry urging it to include Covovax in the national COVID-19 vaccination drive for 12 years and above.

Singh stated that the Pune-based firm wants to provide Covovax to private hospitals at Rs 900 per dose plus GST and is also waiting for directions to supply the vaccine to the Centre but has not mentioned the price.